| Stereochemistry | ABSOLUTE |
| Molecular Formula | C30H24N4O10 |
| Molecular Weight | 600.5324 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O[C@]2(COC(=O)C1=CC=CN=C1)O[C@H](COC(=O)C3=CN=CC=C3)[C@@H](OC(=O)C4=CC=CN=C4)[C@@H]2OC(=O)C5=CC=CN=C5
InChI
InChIKey=FUWFSXZKBMCSKF-ZASNTINBSA-N
InChI=1S/C30H24N4O10/c35-26(19-5-1-9-31-13-19)40-17-23-24(42-28(37)21-7-3-11-33-15-21)25(43-29(38)22-8-4-12-34-16-22)30(39,44-23)18-41-27(36)20-6-2-10-32-14-20/h1-16,23-25,39H,17-18H2/t23-,24-,25+,30-/m1/s1
| Molecular Formula | C30H24N4O10 |
| Molecular Weight | 600.5324 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Nicofuranose is a niacin derivative used as a hypolipidemic agent. The Nicofuranose administration leads to inhibition of free fatty acid turnover and consequently a marked reduction in triglyceride turnover. Nicofuranose, unlike clofibrate, did not affect the mechanisms responsible for the clearance of plasma triglycerides.
